TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial (Q27853024)

PubMed

24957073

13 November 2016

title

TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial (English)

1 reference

PubMed

13 November 2016

1 reference

7

0 references

Gina Brown

Gina Brown

11

0 references

Josep Tabernero Caturla

Josep Tabernero

6

0 references

David Cunningham

David Cunningham

3

0 references

Andrew Wotherspoon

10

Andrew Wotherspoon

0 references

Alice Dewdney

9

Alice Dewdney

0 references

Jacqueline Oates

13

Jacqueline Oates

0 references

Ian Chau

14

Ian Chau

0 references

author name string

Francesco Sclafani

1

0 references

David Gonzalez

2

0 references

Sanna Hulkki Wilson

4

0 references

Clare Peckitt

5

0 references

Andrés Cervantes

8

0 references

Diana Tait

Journal of the National Cancer Institute

12

0 references

language of work or name

English

0 references

publication date

July 2014

0 references

published in

0 references

volume

106

0 references

issue

7

0 references

cites work

Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU121

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU121

P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU121

p53 modulates acquired resistance to EGFR inhibitors and radiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU121

P53 and PTEN expression contribute to the inhibition of EGFR downstream signaling pathway by cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU121

Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU121

Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU121

Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU121

Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU121

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU121

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU121

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU121

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU121

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU121

A new p53 target gene, RKIP, is essential for DNA damage-induced cellular senescence and suppression of ERK activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU121

Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU121

PRAK is essential for ras-induced senescence and tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU121

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU121

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU121

Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU121

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU121

Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU121

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJU121

0 references

24957073

1 reference

PubMed

24957073